White House drug czar says cannabis is “still illegal” after rescheduling (Newsletter: May 11, 2026)
#55 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians need to understand that despite the DEA’s rescheduling decision, the White House maintains that cannabis remains federally illegal, creating a confusing legal landscape that affects prescribing practices, liability exposure, and patient counseling. This legal ambiguity is particularly important as older adults increasingly view cannabis as a therapeutic alternative, requiring clinicians to be informed about both the actual regulatory status and the evidence base for cannabis use in their patient populations. The concurrent progress on psilocybin and psychedelic treatments in multiple states signals that clinicians should expect evolving regulations around these substances and should stay current on emerging clinical evidence to guide patient discussions about these treatment options.
Despite the DEA’s May 2024 rescheduling of cannabis to Schedule III, the White House Office of National Drug Control Policy has clarified that cannabis remains federally illegal under the Controlled Substances Act, creating ongoing legal ambiguity for prescribers and patients. This apparent contradiction between rescheduling and continued illegality reflects the complex regulatory landscape in which clinicians must navigate cannabis recommendations, particularly as older adults increasingly view cannabis as a therapeutic alternative to conventional medications. While some states have moved forward with psychedelic-assisted therapy frameworks (as evidenced by Minnesota’s psilocybin amendment and Louisiana’s psychedelic treatment ballot measures), the federal prohibition status of cannabis undermines consistent clinical guidance, insurance coverage, and research opportunities at the national level. Clinicians should counsel patients that state-level legality does not equate to federal approval, and that documentation and liability exposure remain significant concerns when discussing or recommending cannabis-based therapeutics. The practical takeaway is that prescribers must remain cautious about cannabis recommendations until federal policy achieves clarity, and should counsel patients to verify local and state regulations before use.
“The disconnect between rescheduling and enforcement only creates confusion for my patients who are trying to make informed decisions about their treatment options, and it undermines the clinical work we’re doing to establish evidence-based cannabis protocols in primary care.”
? The persistence of federal cannabis prohibition despite rescheduling represents an ongoing source of clinical and legal ambiguity that practitioners should monitor, particularly as patient demand for cannabis as an alternative to conventional medications continues to grow, especially among older adults. The disconnect between state-level legalization, rescheduling actions, and maintained federal illegality creates conflicting guidance for clinicians who may encounter patients seeking cannabis for symptom management—a population that may be motivated by legitimate concerns about pharmaceutical side effects or drug interactions. Concurrently, the expanding legal landscape around psychedelics (as reflected in state-level psilocybin and psychedelic treatment initiatives) adds another layer of complexity to discussions about alternative and adjunctive therapies. Clinicians should remain informed about both the state and federal regulatory status of these substances in their jurisdictions, document patient inquiries and clinical reasoning carefully, and maintain awareness that evidence quality and legal status do not always align.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
